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Summary
Flt-4, a VEGF receptor, is activated by its specific ligand, VEGF-C. The resultant signaling pathway promotes angiogenesis
and/or lymphangiogenesis. This report provides evidence that the VEGF-C/Flt-4 axis enhances cancer cell mobility and in-
vasiveness and contributes to the promotion of cancer cell metastasis. VEGF-C/Flt-4-mediated invasion and metastasis of
cancer cells were found to require upregulation of the neural cell adhesion molecule contactin-1 through activation of the
Src-p38MAPK-C/EBP-dependent pathway. Examination of tumor tissues from various types of cancers revealed high levels
of Flt-4 and VEGF-C expression that correlated closely with clinical metastasis and patient survival. The VEGF-C/Flt-4 axis,
through upregulation of contactin-1, may regulate the invasive capacity in different types of cancer cells.Introduction
Tumor invasion andmetastasis are the critical steps in determin-
ing the aggressive phenotype of human cancers and are the
major causes of cancer deaths (Steeg, 2003). Several sets of
growth factors and their cognate receptors have been reported
to be importantly involved in regulation of tumor invasion and
metastasis (Avraham et al., 2000). Thus, disruption of the growth
factor and receptor axis is a current strategy for the develop-
ment of anticancer drugs (Kerbel and Kamen, 2004).
Production and secretion of VEGFs is commonly observed in
most aggressive tumors, and expression of VEGFs profoundly
influences the prognosis of cancer patients (Alitalo and Carme-
liet, 2002; Kerbel and Kamen, 2004). VEGF is one of the most
potent stimulators of angiogenesis identified thus far, affecting
endothelial cell proliferation and motility and vascular perme-
ability (Kerbel and Kamen, 2004). VEGFs exert their angiogenic
functions through activation of the tyrosine kinase receptorsCANCER CELL 9, 209–223, MARCH 2006 ª2006 ELSEVIER INC. DOI 10VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), which are ex-
pressed primarily by endothelial cells (Ferrara and Davis-Smyth,
1997) but also by a wide variety of cancer cell lines (Boocock
et al., 1995; Hendrix et al., 2003; Strizzi et al., 2001). These find-
ings suggest that the physiological role of the VEGF signaling
pathway extends beyond angiogenesis in cancer. VEGFR-2
has been found to be expressed in melanoma and mesotheli-
oma (Strizzi et al., 2001) cell lines, and treatment of those cells
with VEGF-A results in increased proliferation via activation of
VEGFR-2. Additionally, VEGF-A has been found to induce acti-
vation of MAPK(s) and promote growth of cancer cells (vonMar-
schall et al., 2000) through activating VEGFR-2 signaling.
VEGFR-3 (or Flt-4), another VEGF receptor, is activated by its
specific ligand, VEGF-C, resulting in promotion of angiogenesis
and/or lymphangiogenesis (Alitalo and Carmeliet, 2002; Plate,
2001; Skobe et al., 2001). In addition to its expression on lym-
phatic endothelial cells (LECs), the Flt-4 has been shown to be
expressed in a variety of human malignancies, including lungS I G N I F I C A N C E
Metastasis is themain cause of morbidity andmortality in most cancer patients. Flt-4 and VEGF-C are recognized to play an important
role in metastasis via promotion of lymphangiogenesis. This report provides evidence that activation of the VEGF-C/Flt-4 axis also en-
hances mobility of cancer cells and contributes to the promotion of metastasis in animals. The function and molecular mechanism of
the VEGF-C/Flt-4 axis, which were revealed from in vitro and in vivo studies and from examination of patient outcomes, provide insight
into the process of tumor metastasis in cancer patients..1016/j.ccr.2006.02.018 209
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A R T I C L EFigure 1. Flt-4 is expressed at membrane location in human tumor tissues
A: Immunohistochemical staining of human lung adenocarcinoma tissues. Arrows indicate lymphatic vessels; T, tumor. B: Strong staining of Flt-4 was observe
in tissues of patients with invasive or advanced stage disease. Arrows indicate lymphatic vessels; T, tumor.C: Staining with the normal mouse IgG as the contr
D: Weak staining of Flt-4 in lung adenocarcinoma specimens. Arrows indicate lymphatic vessels; T, tumor. E and G: Strong staining of Flt-4 (E) and VEGF-C (
was observed both in lymph node metastatic tumors and normal part of the same specimen. T, tumor; arrows indicate expression of Flt-4 or VEGF-C in norm
parts. F and H: Control stained with the normal mouse IgG; T, tumor. I: Normalized Flt-4 mRNA expression of tumor and matched normal tissue were measure
by quantitative RT-PCR in 195 specimens. T, tumor tissue; N, matched normal tissue. J: Combined expression of VEGF-C and Flt-4 proteins correlates inverse
with survival of patients with lung adenocarcinoma. The p value refers to the comparison between both high and both low groups.210 CANCER CELL MARCH 2006
A R T I C L ETable 1. Clinicopathologic characteristics of patients with associated combined expression of VEGF-C and Flt-4: Both low, intermediate, or both high staining
Characteristic Both lowa (n = 18) Intermediate (n = 20) Both high (n = 27) p value
Age (mean 6 SD) (in years) 62.3 6 10.0 54.3 6 12.5 63.4 6 12.3 0.03b
Sex, no. of patients
Male 8 9 10 0.82
Female 10 11 17
Stage,d no. of patients
I–II 15 11 10 0.01
III–IV 3 9 17
Tumor status,d no. of patients
T1 6 7 5 0.38
T2–T4 12 13 22
Nodal status,d no. of patients
N0 16 10 4 <0.001
N1–N3 2 10 23
Median survivale (median 6 SD) (in months) Not been reached yet 21.9 6 2.9 18.2 6 5.0 0.018c
aBoth low indicates that expression of both Flt-4 and VEGF-C in tumor cells is low; intermediate indicates that expression of either Flt-4 or VEGF-C, but not both,
in tumor cells is high; both high indicates that expression of both Flt-4 and VEGF-C in tumor cells is high.
bDerived with a one-way ANOVA test.
cDerived with log-rank test; other p values were derived with Pearson chi-square tests. All statistical tests are two sided. SD, standard deviation.
dThe tumor stage, tumor status, and nodal status were classified according to the international system for staging lung cancer.
eThere was one patient from the both low group and one patient from the both high group who died within 30 days of operation, and they were not included
in the survival analysis.adenocarcinoma (Li et al., 2003), colorectal adenocarcinoma
(Witte et al., 2002), head and neck carcinomas (Neuchrist
et al., 2003), prostate carcinoma (Kaushal et al., 2005), leukemia
(Dias et al., 2002), and Kaposi’s sarcoma (Weninger et al., 1999).
Expression of Flt-4 was also reported to correlate significantly
with the different stages of cervical carcinogenesis (Van Trap-
pen et al., 2003). These observations suggest that Flt-4’s ligand,
VEGF-C, may affect cancer development or progression by di-
rect effects on tumor cells. Unlike the well-characterized axes
of VEGF-A and VEGFR-1/R-2, neither the signaling pathway ac-
tivated by the interaction between VEGF-C and Flt-4 in epithelial
tumor cells nor the biological significance of activation of this
axis is understood.
We conducted these studies to characterize the VEGF-C/Flt-4
axis, and we found that it plays an important role in promoting
invasion and metastasis of human lung adenocarcinoma cells.
Results
Expression of VEGF-C and Flt-4 correlates with stage
and lymph node metastasis of cancers and survival
of cancer patients
To ascertain whether the VEGF-C-specific receptor Flt-4 is ex-
pressed in cancer cells, we analyzed a total of 218 human can-
cer specimens using a monoclonal antibody specific against
Flt-4 (MAB904, from R&D Systems). Figure 1A shows that
Flt-4 was detectable in the tumor epithelium and surrounding
lymphatic vessels. Strong staining for the Flt-4 on the cytoplas-
micmembranewas frequently observed in invasive or advanced
stage lung adenocarcinoma (Figure 1B); this staining was not
detected when normal mouse IgG (Figure 1C) was used. In con-
trast, negative or very weak staining of Flt-4 was seen in early-
stage lung adenocarcinoma (Figure 1D). We used two additional
specific antibodies against Flt-4, MAB3491 (R&D Systems) and
sc-282976 (Santa Cruz Biotechnology), to confirm the presence
of the Flt-4 and found similar expression patterns (Figures S1A–
S1D in the Supplemental Data available with this article online).
An important finding was that metastatic tumor cells in theCANCER CELL MARCH 2006lymph node frequently had high expression of Flt-4 and VEGF-C
(Figures 1E and 1G). A number of Flt-4-stained lymphatic ves-
sels were distributed around the metastatic tumors in the lymph
nodes (Figure 1E). The specificity of the antibodies’ recognition
of Flt-4 and VEGF-C was confirmed by using normal mouse IgG
control (Figures 1F and 1H). This observation is consistent with
existence of a VEGF-C/Flt-4 autocrine loop in highly invasive hu-
man lung adenocarcinoma.
Flt-4 protein and mRNA were also strongly expressed in var-
ious other types of advanced cancer, including cervical, breast,
prostate, and colorectal, as detected by immunohistochemical
staining and a fluorescence in situ hybridization (FISH) assay
(Figures S1E and S1F), suggesting that expression of VEGF-C
and Flt-4 may be a general phenomenon in multiple cancer
types. The FISH assay showed that strong staining for Flt-4
mRNA also occurred frequently in tissue from advanced stage
tumors and that this positive staining was not detected when
the sense control probe was used (Figure S1F). These results
were consistent with the immunohistochemical data. We also
detected the expression levels of Flt-4 mRNA in normal and
matched tumor tissues by quantitative reverse transcription
(RT)-PCR (Figure 1I) and FISH (Figure S1G). Both results indi-
cated that expression of Flt-4 mRNA in tumor tissues was higher
than it was in matched normal tissues.
Patients whose tumors expressed high levels of both VEGF-C
and Flt-4 were more likely than those having tumors expressing
low or intermediate levels of these proteins to have advanced
disease and lymph node metastasis. The relationships between
the level of VEGF-C/Flt-4 expression and the clinicopathological
characteristics of the lung adenocarcinomas are summarized in
Table 1. Most importantly, patients having tumors with high ex-
pression levels of both VEGF-C and Flt-4 had the shortest sur-
vival time of all three groups (Figure 1J).
The VEGF-C/Flt-4 axis promotes migration and invasion
of cancer cells
Through use of flow cytometric analyses, expression of the Flt-4
was found to be elevated in the highly invasive CL1-3 and CL1-5211
A R T I C L EFigure 2. Flt-4/VEGF-C axis regulates invasion ability of human cancer cells
A: Upper panel: FACScan analysis of expression of Flt-4 protein. Lower panel: in vitro invasiveness of cancer cell lines as measured by the Boyden chamber
assay.
B: Expression of RNAs for the Flt-4 and VEGF-C genes in cancer cells.
C: Treatment with 50 ng/ml VEGF-C, 50 ng/ml VEGF-C (Cys156Ser), or 50 ng/ml VEGF-A in H928 cells and measurement of the migration and invasiveness of
cancer cells (*p < 0.05, two-tailed Student’s t test). Growth pattern of H928 cells was detected by trypan blue exclusion assay. Each treatment was performed
in three separate experiments.
D: H928 cells were incubated with 50 ng/ml VEGF-C for 30 min, and tyrosine-phosphorylated Flt-4 was detected by immunoprecipitation and Western blotting
(IP-Western blotting).212 CANCER CELL MARCH 2006
A R T I C L Elung cancer cells, but its expression was barely detectable in the
poorly invasive parental CL1-0 cells (Figure 2A). A549 cells,
which have strong invasive activity, expressed the Flt-4 more
abundantly than H928 and H1299 cells, which have low invasive
activity (Figure 2A). RT-PCR analysis revealed that the levels of
VEGF-C and Flt-4 mRNA were coordinately increased in highly
invasive cell lines such as CL1-3, CL1-5, and A549 (Figure 2B).
Although Flt-4 mRNA was significantly elevated in H928 cells,
VEGF-C mRNA was present at very low levels. Accordingly,
the invasive activity of H928 cells was much lower than that of
CL1-3, CL1-5, and A549 cells.
The axis of VEGF-C and Flt-4 was also expressed in other
cancer cell lines, including breast, cervical, colorectal, and pros-
tate. More importantly, the levels of VEGF-C and Flt-4 mRNA
were also more abundant in the highly invasive MDA-MB-231
breast cancer cell line and the SiHa cervical cancer cell line
(Figure 2B). The coordinate expression of VEGF-C and Flt-4 in
some of these tumor cell lines raised the possibility that an auto-
crine loop exists in these lines.
In vitromigratory and invasive activity assayswere used to ex-
amine the role of the VEGF-C/Flt-4 axis in the invasiveness of
these cancer cells. Treatment with 50 ng/ml of recombinant hu-
man VEGF-C or VEGF-C (Cys156Ser) protein, which is a selec-
tive agonist of Flt-4 and does not bind KDR (Joukov et al., 1998),
significantly increased themigratory activity and invasiveness of
H928 human lung adenocarcinoma cells (Figure 2C). These data
suggest that native VEGF-C and VEGF-C (Cys156Ser) show
similar potential for increase cell mobility. To rule out the possi-
bility that the effect of VEGF-C on invasiveness was caused by
different proliferation rates, we compared the growth rates of
VEGF-C-overexpressing cells and control cells in serum-free
and in anchorage-independent culture conditions, respectively.
The control cells and the VEGF-C-overexpressing cells had sim-
ilar growth rates (Figure S2A).
Stimulation with recombinant VEGF-C (Cys156Ser), but not
with VEGF-A, led to a significant increase in tyrosine phosphor-
ylation of the Flt-4 in H928 cells but not in HL-60 cells, which
have been shown to express KDR but not Flt-4 (Figure 2D and
Figure S2B). Indeed, VEGF-A treatment stimulated an evident
increase in tyrosine phosphorylation of KDR in HL-60 cells and
induced cell proliferation in HUVEC cells (Figures S2B and
S2C). These findings imply that Flt-4 receptors, but not KDR re-
ceptors, in H928 cells are functionally active and fully responsive
to VEGF-C. It is interesting to note, however, that there were two
major forms of Flt-4 in LECs,w125 kDa andw195 kDa, but only
thew125 kDa form was detected in lung adenocarcinoma cells
and leukemia cells (Figure S2D). It has been reported that two
forms of Flt-4 transcript are generated by alternative polyadeny-
lation and alternative splicing (Pajusola et al., 1993). Consistent
with this report, we found that both long and short forms of Flt-4
were present in LECs but only the short form of Flt-4 could beCANCER CELL MARCH 2006detected in A549 and H928 lung adenocarcinoma cells using
the RNase protection assay (Figure S2D).
To construct a condition suitable for manifestation of an auto-
crine loop, a human VEGF-C cDNAexpression vector and a con-
trol vector were stably transfected into different type of cancer
cells. As shown in Figure 2E, the VEGF-C-transfected H928 cells
displayed significantly increased tyrosine phosphorylation of the
Flt-4 as compared with vector-transfected controls. A notice-
able (2- to 3-fold) increase in the invasive ability of VEGF-C-
overexpressing cancer cells was observed compared with vec-
tor controls in different type of cancer cells (Figure 2E).
A549 cells expressed both VEGF-C and Flt-4 mRNA at high
concentrations (Figure 2B), consistent with the presence of a
VEGF-C/Flt-4 autocrine loop. Recombinant Flt-4/Fc, which
has been shown to specifically neutralize the secreted form of
VEGF-C, was therefore utilized to interrupt a potential loop in
these cells. Treatment with recombinant Flt-4/Fc effectively de-
creased the extent of Flt-4 tyrosine phosphorylation (Figure 2F).
However, the recombinant KDR/Fc, which specifically antago-
nizes the effects of VEGF-A, failed to alter the phosphorylation
status of Flt-4 in A549 cells (Figure 2F). Under the same treat-
ment conditions, recombinant Flt-4/Fc, but not KDR/Fc, dimin-
ished the invasiveness of A549 cells by 70% (Figure 2F). Al-
though KDR/Fc failed to inhibit the Flt-4 activation by VEGF-C,
it effectively diminished the KDR activation as well as the prolif-
eration of HUVEC cells by stimulation with VEGF-A (Figure S2C).
As an alternative approach, dominant-negative inhibition of
innate Flt-4 through overexpression of tyrosine kinase domain-
deleted Flt-4 (Flt-4DTK) was used. In A549 cells expressing
Flt-4DTK, the VEGF-C/Flt-4 autocrine loop became defective
because of the dramatic reduction in Flt-4 phosphorylation
(Figure 2G). The expression of truncated Flt-4 in A549, MDA-
MB-231, and C33A cells also strongly impaired their endoge-
nous and VEGF-C- or VEGF-C (Cys156Ser)-induced invasive
capacity (Figure 2G). These findings, in conjunction with those
described above, strongly support our hypothesis that the
VEGF-C/Flt-4 affiliation is actively involved in regulating the in-
vasiveness of cancer cells.
To define the relative importance of the VEGF-C/Flt-4 axis in
metastasis, we compared the VEGF-C/Flt-4 axis with other
well-known mechanisms of cancer metastasis such as the
EGFR (Lu et al., 2003) and CXCR4 pathways (Li et al., 2004).
The results of our in vitro invasion assay showed that blockade
of the VEGF-C/Flt-4 axis by Flt-4/Fc had inhibitory effects on cell
invasiveness similar to those of the EGFR inhibitor ZD1839 (2.5
mM) in A549 cells. Furthermore, we found that blockade of the
VEGF-C/Flt-4 axis by Flt-4/Fc resulted in a more efficient inhib-
itory effect on cell invasion than did blockade of the CXCR4
pathway by the CXCR4 inhibitor AMD3100 (10 mM) (Figure S2F).
These data suggested that the VEGF-C/Flt-4 axis plays as im-
portant a role in the invasiveness of lung adenocarcinoma cellsE: Left upper panel: analysis of VEGF-C mRNA expression by RT-PCR and Flt-4 activation by IP-Western blotting. Left lower panel and right panel: measurement
of the invasiveness by the Boyden chamber assay. The invasive activity was significantly higher in VEGF-C-transfected cells as compared to vector control
cells, as indicated by the asterisks (*p < 0.05).
F: A549 cells were treated with 100 ng/ml Flt-4/Fc for 30 min followed by analyses of tyrosine phosphorylation of Flt-4 (upper panel) or for 48 hr followed by
analyses of cell invasiveness. *p < 0.05, two-tailed Student’s t test. The fold estimation of protein expression is indicated by the numbers below the lanes.
G: Left upper panel: Flt-4 tyrosine phosphorylation in A549/Flt-4DTK cells was detected by IP-Western blotting assay. Arrow indicates kinase domain-deleted Flt-
4 protein. Left lower panel: the invasion abilities of A549/vector and A549/Flt-4DTK cells. Right panel: treatment with VEGF-C or VEGF-C (Cys156Ser) in cells
expressing control vector or Flt-4DTK expression vector and analysis of the invasive activity of cells. *p < 0.05, two-tailed Student’s t test.213
A R T I C L Eas EGFR does and that this axis is more critical than CXCR4 is in
cell invasion.
CNTN-1 acts as a downstream effector
in VEGF-C/Flt-4-induced invasion and metastasis
To study the downstream effector genes of VEGF-C/Flt-4 sig-
naling, A549 cells were first treated with BSA, rhKDR/Fc, or
rhFlt-4/Fc for 24 hr. Differentially expressed genes were then
identified with a customized GEArray cDNA array containing
cDNA sequences corresponding to functions related to cell ad-
hesion and migration. Under the highly stringent conditions we
used, the neural adhesionmoleculeCNTN-1 genewas identified
as one of the highly decreased genes in rhFlt-4/Fc-treated cells,
but not in rhKDR/Fc-treated or control A549 cells (Figure 3A and
Table S1). In support of this finding, treatment with rhFlt-4/Fc,
but not with rhKDR/Fc, decreased expression of CNTN-1
mRNA and protein (Figure 3A). A similar reduction of CNTN-1
protein was seen in A549 cells overexpressing Flt-4DTK (Fig-
ure 3A). Levels of CNTN-1 mRNA and protein were similarly re-
duced in rhFlt-4/Fc-treated CL1-5 cells, which also possess
a VEGF-C/Flt-4 autocrine loop (data not shown). In H928 cells,
increasing concentrations of VEGF-C increased the expression
of CNTN-1 protein in a dose-dependent manner (Figure 3B).
Treatment with VEGF-C increased CNTN-1 mRNA and protein
to their optimum concentrations at 8 hr and 24 hr, respectively
(Figure 3B). In agreement with the findings described above,
VEGF-C-transfected H928 (H928/VEGF-C) cells exhibited a
3.3-fold elevation of CNTN-1 protein compared with that of con-
trol cells (Figure 3B).
To search for additional functional linkages between CNTN-1-
and VEGF-C/Flt-4-mediated cell invasion, the level of CNTN-1 in
H928/VEGF-C cells was knocked down by transfection with dif-
ferent CNTN-1-specific RNAi expression vectors (siRNA-1,
siRNA-2, and siRNA-3). Figure 3C shows that different clones
separately transfected with different CNTN-1-specific RNAi all
inhibited the expression of CNTN-1 protein in H928/VEGF-C
cells. Among them, the siRNA-2-1-expressing clone seemed
to be themost effective in inhibiting CNTN-1 protein expression.
As anticipated, transfection with siRNA-2 also effectively
reduced the invasiveness of H928/VEGF-C, MDA-MB-231/
VEGF-C, and C33A/VEGF-C cells (Figure 3C). Stable transfec-
tion of A549 cells with the siRNA-2 expression vector resulted
in greatly reduced expression of CNTN-1 protein as well as
cell invasion capacity (Figure 3D). Thus, the results obtained
here show that CNTN-1 is involved in cancer cell invasiveness
and acts as a downstream effector of VEGF-C/Flt-4 signaling.
F-actin is continuously polymerized and depolymerized in
motile cells and is essential to cell motility (Cooper, 1991). To fur-
ther assess whether VEGF-C-induced CNTN-1 expression pro-
motes cell invasion via arrangements of the actin cytoskeleton,
A549, H928/vector, and H928/VEGF-C cells transfected with
or without siRNA-2 were therefore stained with rhodamine-
conjugated anti-phalloidin antibody and characterized using
multicolor immunofluorescence and confocal laser scanning
microscopy. The A549 control cells displayed well-formed
F-actin-containing microfilament bundles within the cytoplasm
and below the plasma membrane, whereas the A549/siRNA-2
cells contained few microfilament bundles (Figure 3D). Further-
more, the H928/VEGF-C cells displayed well-formed F-actin-
containing microfilament bundles, which could be abolished
by siRNA-2 (Figure 3E). These findings indicated that VEGF-214C-induced CNTN-1 expression regulates rearrangements of
F-actin-containing microfilament bundles, suggesting that
F-actin-containing microfilament bundle rearrangement may
be involved in the VEGF-C-induced CNTN-1-mediated cell inva-
siveness.
To define whether the correlation between Flt-4 expression
and CNTN-1 expression exists in lung adenocarcinoma, we im-
munohistochemically analyzed the levels of Flt-4 and CNTN-1
proteins in such tumors. We found that expression of CNTN-1
was tightly correlated with the expression of Flt-4 in these
tumors (correlation coefficient = 0.644; p < 0.001; Table S2). In
addition, the expression of CNTN-1 in lung adenocarcinoma
correlated with tumor stage, lymph node metastasis, and
patient survival (Table S3).
The Src/p38 MAPK-mediated C/EBP signaling
pathway is required for VEGF-C/Flt-4-mediated
CNTN-1 expression
To investigate the pathways associated with CNTN-1 induction
in response to VEGF-C/Flt-4 signaling, we examined the forms
of MAP kinases (MAPKs) that are reported to function in the reg-
ulation of cell invasion (Suyama et al., 2002). Western blot anal-
ysis revealed that phosphorylated p38MAPK, but not ERK1/2 or
JNK, was increased in VEGF-C-overexpressing H928 cells (Fig-
ure 4A; approximately 2.7-fold higher than in control cells). Fur-
thermore, expression of Flt-4DTK reduced p38 MAPK phos-
phorylation in A549 cells (Figure 4A). Treated with various
specific MAPKs inhibitors or vehicles, only the p38 MAPK-spe-
cific inhibitor SB203580 reduced CNTN-1 expression to a signif-
icant degree in H928/VEGF-C cells (Figure 4B; 72% inhibition
relative to that in control cells). In contrast, treatment with the
ERK1/2 or JNK inhibitors PD98059 or SP600125, respectively,
failed to diminish CNTN-1 expression (Figure 4B). As further ev-
idence for the involvement of p38 MAPK-dependent signaling in
regulation of CNTN-1 expression, kinase activity was blocked
by expressing the dominant-negative p38 (p38AF). VEGF-C/
Flt-4 signaling-induced activation of p38 MAPK and upregula-
tion of CNTN-1 were both abolished by transfection with
p38AF (Figure 4B).
Cytoplasmic tyrosine kinases of the Src family have been im-
plicated in the transduction of extracellular signals from mem-
brane receptors (including RTKs) to downstream cellular effec-
tors and in the regulation of cancer cell mobility (Tanaka et al.,
2004). The potential role of Src in VEGF-C-mediated p38
MAPK activation and subsequent CNTN-1 induction was there-
fore of interest. Src kinase activity was inhibited either by treat-
ment with PP1 (specific for Src-like kinase) or by expression of
a kinase-defective Src mutant (DN-src carrying a K-to-D muta-
tion at position 297). Both approaches resulted in strong reduc-
tions in p38MAPK activation and subsequent CNTN-1 induction
(Figure 4C). In addition, treatment with VEGF-C induced a 6.3-
fold induction of CNTN-1 promoter activity; this induction was
abolished by SB203580 and PP1 but not by PD98059 (Fig-
ure 4D).
To further determine which response element participates in
the regulation of CNTN-1 promoter activity in response to
VEGF-C, we developed a series of CNTN-1 promoter-reporter
mutation constructs (Figure 4E). Database analysis by
TFSEARCH program (version 1.3) of the 994 bp CNTN-1 pro-
moter for known consensus sequences indicated the presence
of binding sites for Sp-1, Oct-1, C/EBP, and AP-1 (Figure 4E). InCANCER CELL MARCH 2006
A R T I C L EFigure 3. VEGF-C/Flt-4 axis regulates cancer cell invasion via CNTN-1-dependent F-actin rearrangement in cancer cells
A: Upper panel: CNTN-1 expression in control, Flt-4/Fc, and KDR/Fc cells as determined by cDNA array imaging. Arrows indicate CNTN-1. Lower panel: CNTN-1
expression as determined by RT-PCR and Western blotting.
B: Expression of CNTN-1 in VEGF-C-treated H928 cells. Left upper panel: H928 cells were treated with various concentrations of VEGF-C for 24 hr, followed by
measurement of CNTN-1 protein expression by Western blotting. Left lower panel: H928 cells were treated with 50 ng/ml VEGF-C for the indicated times and
the expression of CNTN-1 mRNA and protein determined by RT-PCR and Western blot, respectively. Right panel: CNTN-1 protein expression in H928/vector or
H928/VEGF-C cells was measured by Western blot. The fold estimation of protein expression is indicated by the numbers below the lanes.
C: CNTN-1 protein expression and cell invasiveness of vector and VEGF-C-overexpressing cells stably transfected with control (ctrl) or CNTN-1-specific siRNA
was analyzed by Western blot and Boyden chamber assay. Asterisks denote a statistically significant difference compared with values of lane 1 (*p < 0.05).
D: Left panel: CNTN-1 protein expression and invasiveness in A549 cells stably transfected with CNTN-1-specific RNAi expression vector or control vector. Right
panel: fluorescent staining of F-actin by rhodamine-conjugated phalloidin.
E: Fluorescent staining of F-actin by rhodamine-conjugated phalloidin.
CANCER CELL MARCH 2006 215
A R T I C L EFigure 4. Involvement of Src kinase, p38 MAPK, and C/EBPa in CNTN-1 upregulation during activation of the VEGF-C/Flt-4 axis
A: Western blot analyses of the phosphorylation of MAPKs.
B:VEGF-C/Flt-4 axis-mediated CNTN-1 upregulation via p38 MAPK. Left panel: H928/VEGF-C cells were treated with PD98059 (PD; 25 mM), SB203580 (SB; 10 mM),
or SP 600125 (SP; 20 mM) for 2 hr, and expression of CNTN-1 and b-actin was analyzed by Western blot. Right panel: cells were transfected with control vector or
dominant-negative p38 MAPK expression vector (p38AF), and CNTN-1 expression was then analyzed by Western blot.
C: H928/vector and H928/VEGF-C cells were treated with 10 mM PP1 (left panel) or transfected with 3 mg of dominant-negative src (DN-src) (right panel), and
protein expression was then measured by Western blot analysis.216 CANCER CELL MARCH 2006
A R T I C L Eaddition, VEGF-C significantly increased luciferase activity in
pCNTN-Luc-transfected cells and pCNTN-LucD2-transfected
cells but not in pCNTN-LucD1-transfected cells. VEGF-C-
induced CNTN-1 promoter activity decreased about 80% by
point mutation of the C/EBP response element on pCNTN-
LucD2 (pCNTN-LucD2mC/EBP) but had no effects on pCNTN-
LucD2mAP-1 or pCNTN-LucD2mOct-1 (Figure 4E).
We next investigated whether VEGF-C-induced C/EBP asso-
ciates with CNTN-1 promoter by using a chromatin immunopre-
cipitation (ChIP) assay. Using different transcription factors and
specific antibodies, we found that C/EBPa, but not other tran-
scription factors, associates with the CNTN-1 promoter after
treatment with VEGF-C in H928 cells (Figure 4F) and C33A
and MDA-MB-231 cells (data not shown). In addition, the
VEGF-C-induced C/EBPa-DNA complex could be abolished
by SB203580 and PP1 but not by PD98059 (Figure 4F). In a par-
allel ChIP experiment to test the specificity of chromatin associ-
ation, Oct-1 and c-jun were recruited to the thioredoxin reduc-
tase 1 (TrxR1) and the transforming growth factor b1 (TGFb1)
promoters, respectively, which are the documented targets of
Oct-1 and c-jun (Rundlof et al., 2001; Kim et al., 1990) but not
the CNTN-1 promoter (Figure 4F). Conversely, C/EBPa did not
associate with the TrxR1 promoter or the TGFb1 promoter.
These results demonstrated that the C/EBP site is indeed impor-
tant for VEGF-C-mediated CNTN-1 gene upregulation.
Thus, these studies using pharmacological treatment or ge-
netic inhibition clearly demonstrate that the Src-p38 MAPK-C/
EBPa signaling pathway plays a critical role in the VEGF-C/
Flt-4-mediated upregulation of CNTN-1.
The VEGF-C/Flt-4 axis promotes metastatic colonization
in an animal model
To investigate whether the VEGF-C/Flt-4 axis plays a causal role
in tumor metastasis, we injected H928/vector and H928/
VEGF-C cells subcutaneously into the right flank of SCID
mice, followed by intraperitoneal injections of Flt-4/Fc (0.5
mg/kg/3 days) andmeasured the growth of the resulting primary
tumors every 3 days. H928/VEGF-C and H928/vector tumors
formed at identical rates. Treatment with Flt-4/Fc did not alter
the growth rate of the tumors formed by H928/VEGF-C cells
(Figure 5A), although treatment effectively reduced VEGF-C-
induced Flt-4 activation in primary tumors (Figure 5B). The ex-
pression levels of VEGF-C protein and Flt-4 phosphorylation in
H928/VEGF-C tumors were higher than in the H928/vector tu-
mors (Figure 5B). These results suggested that the VEGF-C/
Flt-4 axis is not required for formation of primary lung tumors.
To further determine whether disruption of Flt-4 activation
would affect the ability of H928/VEGF-C cells to metastasize,
we first examined the metastatic behavior in H928/VEGF-C tu-
mor-bearing mice treated with either Flt-4/Fc or vehicle only.
Whereas tumors expressing the VEGF-C expression vector
formed large numbers of macroscopically visible metastases
in the lungs, those that expressed the control vector formedCANCER CELL MARCH 2006very few metastases (Figure 5C). The numbers of visible meta-
static nodules in mice injected with H928/VEGF-C cells were
higher than those in H928/vector-bearing mice. As shown in
Figure 5C, the mean numbers of metastatic nodules and the oc-
currence of lung metastasis in H928/VEGF-C tumor-bearing
mice treated with Flt-4/Fc were dramatically decreased. In the
Flt-4/Fc-treated H928/VEGF-C group, the mean lymph node
volume was 15.51 mm3, and in the vehicle-treated H928/
VEGF-C group, the mean lymph node volume was 56.80 mm3
(Figure 5D).
In support of these findings, mice bearing A549 primary tu-
mors and treated with Flt-4/Fc or vehicle showed similar tumor
growth rates (Figure 5E). As shown in Figure 5F, the number of
lung metastatic nodules in A549 tumor-bearing mice treated
with Flt-4/Fc decreased dramatically. The mean lymph node
volume was dramatically decreased in the Flt-4/Fc-treated
A549 group (Figure 5G). The expression level of tyrosine-
phosphorylated Flt-4 in both primary tumors and lung meta-
static tumors decreased significantly in the Flt-4/Fc-treated
A549 tumors relative to the vehicle-treated A549 tumors (data
not shown). Together, these data demonstrate that activation
of the VEGF-C/Flt-4 axis promoted tumor metastasis in this an-
imal model.
Subsequently, we used another animal model of experimental
metastasis in which we intravenously injected tumor cells into
the lateral tail vein of mice. The lung metastases that formed oc-
curredmore frequently inmice injected with A549/vector control
cells than in those injected with A549/Flt-4DTK cells (83.3% ver-
sus 16.7%, respectively). A higher occurrence of formed lung
metastases was also observed in mice injected with VEGF-C-
overexpressing H928 (H928/VEGF-C) cells than in mice injected
with H928/vector control cells (58.3% versus 16.7%, respec-
tively).
In addition, the mice injected with H928/vector cells or A549/
Flt-4DTK cells displayed fewer or smaller metastatic nodules in
the lung than did those injected with H928/VEGF-C cells or
A549/vector cells (Figures 6A and 6B). The metastatic tumors
formed in the lungs by the A549/vector and H928/VEGF-C cells
had morphological characteristics typical of adenocarcinoma
(Figure 6C). Moreover, the expression levels of VEGF-C protein
and Flt-4 phosphorylation in the H928/VEGF-C metastatic lung
tumors were higher than they were in the H928/vector tumors
(Figure 6D). Consistent with these data, the levels of Flt-4 phos-
phorylation but not VEGF-C expression in A549/Flt-4DTK
metastatic lung tumors were significantly lower than in the A549/
vector lung metastatic tumors (Figure 6D). Abolition of the
VEGF-C/Flt-4 axis in A549 cells was associated with reduced
formation of metastatic lung nodules. In addition, mice injected
with H928/VEGF-C cells formed more metastatic lung nodules
than mice injected with H928/vector cells. Data from these
two experiments are summarized in Table 2.
Despite these findings, wewanted to further assess the role of
CNTN-1 in VEGF-C/Flt-4-mediated metastatic colonization.D: H928 cells were transfected with 994 bp CNTN-1 promoter-reporter, and the luciferase activity from transfectants was measured. Asterisks denote a statis-
tically significant difference compared with values of lane 1 (*p < 0.05).
E: H928 cells were transfected with various CNTN-1 promoter-reporters or pGL3-basic vector, and the luciferase activity from transfectants was measured.
F: Upper panel: the H928 cells were treated with or without VEGF-C (50 ng/ml) for 4 hr, then processed for ChIP assay using various antibodies. Lower left panel:
the H928 cells were treated with various chemical inhibitors, then processed for ChIP assay using anti-C/EBPa antibody or IgG. Lower right panel: the TrxR-1
promoter and the TGF-b1 promoter were examined by ChIP assay in A549 cells for the occupancy of C/EBPa, Oct-1, and c-jun using anti-C/EBPa, anti-
Oct-1, anti-c-jun, or IgG antibodies.217
A R T I C L EFigure 5. Flt-4/VEGF-C axis is required for lung adenocarcinoma cells to metastasize
A: Growth patterns of subcutaneously xenograft tumors formed by H928/vector cells or H928/VEGF-C cells treated with either vehicle or Flt-4/Fc (0.5 mg/kg/
3 days). Each data point represents the mean 6 SD of eight primary tumors.218 CANCER CELL MARCH 2006
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VEGF-C cells with siCNTN-1 expression vectors or with control
vectors and conducted an in vivo experimental metastasis as-
say. Lung metastases occurred more frequently in the mice in-
jected with H928/VEGF-C/control cells than in those injected
with H928/vector/control cells. This increased occurrence
in vivo was dramatically diminished by knockdown of CNTN-1
in H928/VEGF-C cells. No metastatic nodule formation was ob-
served in the lungs of the mice injected with either H928/
vector/control or H928/vector/siRNA-2-1 cells. Furthermore,
the number of metastatic lung nodules and the lung weight of
mice injected with H928/VEGF-C/siRNA-2-1 cells were signifi-
cantly lower than those in the mice injected with H928/VEGF-C/
control cells. The data from these experiments are summarized
in Table S4. The expression of CNTN-1 protein but not of
VEGF-C or phosphorylated Flt-4 proteins decreased dramati-
cally in H928/VEGF-C/siRNA-2-1 metastatic lung tumors (Fig-
ure 6E). Together, these data demonstrate that VEGF-C/Flt-4-
mediated tumor metastasis required the expression of CNTN-1.
Discussion
Promotion of tumormetastasis by VEGF-C has been reported to
be due to the induction of tumor lymphangiogenesis via effects
of activated Flt-4 on LECs (Alitalo and Carmeliet, 2002; Plate,
2001). It has recently become evident that many tumor cells ex-
press Flt-4, but the functions of this receptor in epithelial cells
are largely unknown. In this study, we found that the VEGF-C/
Flt-4 axis-mediated invasion and metastasis of human cancer
cells were found to require upregulation of the neural cell adhe-
sion molecular CNTN-1 through activation of the Src-p38-C/
EBP-dependent pathway (Figure S3). From in vitro and in vivo
studies to patient outcomes, a function for the VEGF-C/Flt-4
axis in cancer cells was delineated, and further insight was pro-
vided into the process of tumor metastasis.
VEGF-C has been reported to enhance resistance to chemo-
therapy and induction of Bcl-2 in leukemia cells via activation of
Flt-4 and KDR heterodimer (Dias et al., 2002). In our study, treat-
ment with VEGF-C induced tyrosine phosphorylation of Flt-4 but
not of KDR and then increased the cell mobility. Whether the ac-
tivated Flt-4 also contributed to the resistance of chemotherapy
in solid tumors requires further study. VEGF-C has been re-
ported to promote proliferation of leukemia cells (Dias et al.,
2002) via activation of the Flt-4/KDR heterodimer, but we did
not find a similar induction of proliferation in the lung cancer
cell lines we used in this study. Consistent with a previous study
(Dias et al., 2002), we found that KDR could be phosphorylated
by VEGF-C and heterodimerized with Flt-4 in THP-1 leukemia
cells. However, under the same conditions, we detected neither
KDR phosphorylation nor KDR heterodimerized with Flt-4 after
VEGF-C treatment in A549 cells (Figure S2E). This difference
may be a major reason behind the absence of VEGF-C-depen-
dent KDR phosphorylation in our study. It is therefore apparentCANCER CELL MARCH 2006that the functions of the Flt-4 and the cellular responses that oc-
cur on binding of VEGF-C to this receptor vary with cell type.
CNTN-1 associates with two other cell surface proteins be-
lieved to participate in signal transduction. CNTN-1 interacts
in trans with receptor protein tyrosine phosphatase b (RPTPb)
to promote neurite outgrowth (Sakurai et al., 1997), and in cis
with RPTPa (Zeng et al., 1999) to transduce extracellular signals
to Fyn kinase, a member of the Src kinase family that regulates
cell mobility (Umemori et al., 1994). Whether CNTN-1 protein in-
teracts with other proteins that are involved in cancer cell motil-
ity and tumor invasion and metastasis, however, remained to be
determined. Our study demonstrates that CNTN-1 is robustly in-
creased by activation of the VEGF-C/Flt-4 axis and required for
VEGF-C/Flt-4 axis-mediated cell mobility and metastasis.
Flt-4-mediated signaling pathways in LECs have been fully
characterized (Alitalo and Carmeliet, 2002). In contrast, Flt-4-
mediated signaling pathways in epithelial cancer cells have
not been investigated. The findings from this study revealed
that p38 MAPK but not ERK1/2 pathways are activated by over-
expression of VEGF-C in H928 cells (Figure 4A). p38MAPK is re-
ported to function in cell migration and invasion in various can-
cer cells (Ma et al., 2003; Steeg, 2003). Indeed, blockage of the
p38 signaling pathway is associated with inhibition of VEGF-C/
Flt-4-mediated cell invasion. These observations also favor the
proposal that signal transduction in response to activation of
Flt-4 by VEGF-C varies with cell type. Although the PI3-K/Akt
pathway was also activated by VEGF-C/Flt-4 in lung adenocar-
cinoma cells, this pathway was not linked to upregulation of
CNTN-1 or increased cell invasiveness (data not shown). The
Akt pathway is reported to be activated by VEGF-C and to be
important for survival of LECs (Alitalo and Carmeliet, 2002).
VEGF-C/Flt-4-mediated activation of PI3K/Akt signaling may
therefore contribute to biological functions, such as induction
of drug resistance, that are unrelated to invasion of cancer cells.
It has been reported that VEGF-A induces cell migration in leu-
kemia (Dias et al., 2000), multiple myeloma (Podar et al., 2004),
ovarian cancer (Wang et al., 2006), and breast cancer cells
(Bachelder et al., 2002). All of those studies addressed the role
of VEGF-A in migration of cancer cells but not the function of
the VEGF-C/Flt-4 axis. In our study, we found that VEGF-A could
also induce cell migration and invasion in lung adenocarcinoma
cells (Figure 2C). More importantly, we demonstrate that the
VEGF-C/Flt-4 axis is also a regulator of migration and invasion
of cancer cells and that it may have a more potent effect than
VEGF-A has (Figure 2C). These results do not contradict those
of other current studies; instead, we revealed that the VEGF-C/
Flt-4 axis has an important function in promoting the migration
and invasion of cancer cells.
In summary, we provide clinical evidence that Flt-4 and its li-
gand are concurrently expressed in epithelial tumor cells of pa-
tients and that patients who have high levels of expression of
both Flt-4 and VEGF-C have a poorer prognosis than do those
who have high levels of expression of only one of them or lowerB: Expression of VEGF-C protein and tyrosine-phosphorylated Flt-4 was examined by immunoblotting and IP-Western blotting of H928/vector tumors or H928/
VEGF-C tumors treated with or without Flt-4/Fc.
C: Numbers of metastatic nodules in the lung of individual mice carrying different tumors treated with or without Flt-4/Fc.
D: Macroscopic analysis of axillary lymph nodes. Lymph node volume was significantly higher in H928/VEGF-C tumor-bearing mice as compared to H928/
vector tumor-bearing mice, as indicated by the asterisks (*p < 0.05), and this induction could be abolished by treatment with Flt-4/Fc, as indicated by the #.
E: Growth pattern of subcutaneously xenograft tumors formed by A549 cells treated with either vehicle or Flt-4/Fc (0.5 mg/kg/3 days).
F: Total number of metastatic nodules in the lung of individual mice.
G: Macroscopic analysis of axillary lymph node volume. *p < 0.05.219
A R T I C L EFigure 6. Regulation of cancer cell metastasis by the VEGF-C/Flt-4 axis
A and B: Lungs were excised and photographed after experimental metastasis assay. Arrow indicate metastatic tumor nodules.
C: Histologic analyses of lung metastatic tumors. Scale bar, 100 mm.
D: Expression of VEGF-C and tyrosine-phosphorylated Flt-4 protein was examined by immunoblotting of metastatic tumor recovered from lungs of individual
mice.
E: Expression of VEGF-C, CNTN-1 protein, and tyrosine-phosphorylated Flt-4 was examined of lung metastatic tumor from individual mice.levels of expression of both. With respect to themechanisms re-
sponsible for the latter observation, activation of the VEGF-C/
Flt-4 axis in cancer cells promoted their motility and invasive-220ness in vitro and tumor metastasis in vivo. In addition, the
VEGF-C/Flt-4-induced enhancement of cell mobility and inva-
siveness and tumor metastasis was found to be at least partlyCANCER CELL MARCH 2006
A R T I C L ETable 2. Regulation of lung metastasis in the SCID mouse model by the VEGF-C/Flt-4 axis
Lung weight (mg) Lung metastasis
Cell lines Mean 6 SD p value
No. of mice with lung metastasis/
total no. of mice
Median lung
nodules (range) p value
A549/vector 531 6 62 10/12 42.5 (0–72)
A549/FLT-4DTK 467 6 66 p = 0.02a 2/12 2 (0–15) p < 0.001b
H928/vector 440 6 42 2/12 1.27 (0–12)
H928/VEGF-C 489 6 53 p = 0.02a 7/12 13 (0–32) p = 0.014b
aA549/vector versus A549/Flt-4DTK and H928/vector versus H928/VEGF-C by the Student’s t test.
bA549/vector versus A549/Flt-4DTK and H928/vector versus H928/VEGF-C by the Wilcoxon rank-sum test.mediated by upregulation of the adhesion molecule CNTN-1.
These findings and those of others agree that the VEGF-C/
Flt-4 axis has a multifaceted role in tumors via the facilitation
of epithelial tumor cell motility and invasiveness, LEC prolifera-
tion (i.e., lymphangiogenesis), and possibly vascular endothelial
cell proliferation and migration (i.e., angiogenesis). Thus, we
propose that interruption of the VEGF-C/Flt-4 axis may be a
powerful therapeutic approach for controlling tumor growth or
metastasis.
Experimental procedures
In vitro migration assays
Migration of lung adenocarcinoma cells through polycarbonate filters was
examined in 48-well chemotaxis chambers (modified Boyden chambers,
Neuro Probe) as described previously (Kuratomi et al., 1999).
Invasion assays
Modified Boyden chambers with filter inserts (pore size of 8 mm) coated with
Matrigel (40 mg; Collaborative Biomedical, Becton Dickinson Labware) in
24-well dishes (Nucleopore) were employed for invasion assays as described
previously (Shih et al., 2001). Each clone was plated in triplicate for each ex-
periment, and each experiment was repeated at least three times.
Anchorage-independent growth assay
Colony-forming assays in soft agarose were performed as described previ-
ously (Shou et al., 2004). Cells were seeded in 6-well culture dishes in sus-
pensions of 0.35% agar noble in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum on top of a bed of 0.7% agar noble in
the same complete medium. After 3 weeks, tumor cell colonies measuring at
least 50 mmwere counted fromsix replicates per treatment under a dissecting
microscope.
FISH assay
The expression of Flt-4 mRNA in cancer specimens was determined by FISH
assays using Cy-3-UTP-labeled riboprobes. For Flt-4, a probe covering nu-
cleotides 1–595 was selected (Pajusola et al., 1992). Corresponding sense
probes were used as controls. A four-point staining intensity scoring system
was devised for determining the relative expression of Flt-4 mRNA in cancer
specimens; the score ranged from 0 (no expression) to 3 (highest-intensity
staining). The results of the FISH assay were classified in two groups accord-
ing to both the intensity and extent of staining: in the low-expression group,
either no staining was present (staining intensity score = 0) or positive stain-
ing was detected in less than 10% of the cells (staining intensity score = 1),
and in the high-expression group, positive immunostaining was present in
10%–25% (staining intensity score = 2) or more than 25% of the cells (stain-
ing intensity score = 3). All of the FISH assay results were reviewed and
scored independently by two pathologists.
Real-time quantitative RT-PCR
The quality of RNA in samples was determined by electrophoresis through
agarose gels and staining with ethidium bromide; 18S and 28S RNA bands
were visualized with UV illumination. The primers used, based on the cDNA
sequence of Flt-4 (NM 002020), were as follows: 50-AGGGAGACGCCCTTTCANCER CELL MARCH 2006CATG-30 (forward) and 50-GAGGGCTCTTTGGTCAAGCA-30 (reverse) as
described previously (Kaushal et al., 2005). The probe was labeled at the 50
end with carboxyfluorescein and at the 30 end with N,N,N0,N0-tetramethyl-6-
carboxyrhodamine. The primers and probe used for quantitative RT-PCR of
the TATA box binding protein (TBP) mRNA (internal control, GenBank acces-
sion number X54993) were as described previously (Shih et al., 2001). Each
sample was analyzed in duplicate, and amean value was used for further cal-
culation. The TBP was used as an internal control for RNA input. The results
of Flt-4 expression normalized for TBP were presented as a normalized Flt-4
value.
Patients, specimens, and immunohistochemical staining
Tissues utilized were from the Cancer Tissue Core of the National Taiwan
University Hospital. Institutional ReviewBoard approval was obtained to pro-
cure and analyze the tissues used in this study. None of the patients had
received preoperative neoadjuvant chemotherapy or radiation therapy. The
surgical specimens had been fixed in formalin and embedded in paraffin be-
fore they were archived. We used the archived specimens for immunohisto-
chemical staining. Protein expression in the tumor specimens was detected
immunohistochemically as described previously (Su et al., 2004). The same
four-point scoring system and two classification groups that were described
for the results of the FISH assay were also used to assess the results of im-
munohistochemical staining. These results were also reviewed and scored
independently by two pathologists. The histological diagnosis of lung adeno-
carcinomawasmade according to the recommendations of theWorld Health
Organization (WHO, 1999). Tumor size, local invasion, lymph node metasta-
sis, and final disease stage were determined as described previously (Sobin
and Wittekind, 2002). Follow-up of patients had lasted as long as 110
months. Patients who died of postoperative complications within 30 days af-
ter surgery were excluded from the survival analysis. There was one patient
each from both the VEGF-C/Flt-4 high and VEGF-C/Flt-4 low groups who
died within 30 days after surgery.
Statistical analysis
Data are presented as means 6 standard deviations (SD). Student’s t test
was used to compare data between groups. Statistical analyses of clinico-
pathological data were performed as described previously (Shih et al.,
2001). Survival curves were obtained using the Kaplan-Meier method. All sta-
tistical tests included two-way analysis of variance. Statistical significance
was assumed at p values of less than 0.05.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
three supplemental figures, and four supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/3/209/
DC1/.
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